8-K: Hepion Pharmaceuticals Holds Annual Meeting, Votes on Directors and Equity Plan

Hepion Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, auditor ratification, and an amendment to the equity incentive plan.

Summary

• Hepion Pharmaceuticals, Inc. conducted its 2026 Annual Meeting of Stockholders on June 17, 2026.
• As of April 28, 2026, there were 29,119,476 shares of common stock outstanding.
• Shareholders voted to elect five directors: Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula, and Chase LoPriore, to serve until the next annual meeting.
• The appointment of Grassi & Co., CPAs, P.C. as the independent auditors for the fiscal year ending December 31, 2026, was ratified.
• An amendment to the 2023 Omnibus Equity Incentive Plan was approved to increase the number of issuable shares from 200,000 to 8,000,000.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine corporate governance activities with strong shareholder support for management's proposals.

Positives

• All director nominees were elected with a significant majority of 'For' votes.
• The appointment of independent auditors was ratified with overwhelming support.
• The amendment to increase shares under the equity incentive plan received strong approval, indicating support for future employee incentives.
• A substantial number of shares (over 29 million) were outstanding as of the record date.

Future Outlook

The approval of the equity incentive plan amendment suggests a strategy to incentivize future performance and retain talent, which could impact future financial results.

Management Comments

• Gary Stetz, Interim Chief Executive Officer, signed the report on behalf of the company.

Industry Context

StockSavvy.ai notes that the approval of equity incentive plans is a common practice for biotechnology and pharmaceutical companies to attract and retain key scientific and executive talent, crucial for drug development and commercialization.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and approval of the equity plan amendment directly impact shareholder representation and the company's ability to incentivize its workforce.
• Employees: The increased equity pool under the incentive plan provides potential for greater stock-based compensation, aligning employee interests with shareholder value.
• Management: The re-election of directors and the enhanced equity plan support the current leadership and their ability to offer competitive compensation.

Next Steps

• The elected directors will serve until the next annual meeting of stockholders.
• Grassi & Co., CPAs, P.C. will serve as the independent auditors for the fiscal year ending December 31, 2026.
• The company can now issue up to 8,000,000 shares under the amended 2023 Omnibus Equity Incentive Plan.

Key Dates

Keywords

Hepion Pharmaceuticals, Annual Meeting, Stockholders, Directors Election, Independent Auditors, Equity Incentive Plan, Form 8-K, Corporate Governance